SCHEMBL1128655

SCHEMBL1128655

CC(C)(C)OC(=O)N1CCC(c2ccc(B(O)OC(C)(C)C(C)(C)O)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.52
GPR119 Q8TDV5 5/20 0.47
RET P07949 1/20 0.46
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
THRB P10828 1/20 0.46
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43
PTPN6 P29350 1/20 0.43
PDE4B Q07343 1/20 0.43
P2RY14 Q15391 1/20 0.42
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
HPGD P15428 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21747998 0.87 NAMPT (0.55) NAMPTGPR119RETMAPTKDM4E
SCHEMBL12419663 0.85 NAMPT (0.58) NAMPTGPR119RETMAPTKDM4E
SCHEMBL16026530 0.82 KMT2A (0.56) GPR119CRBNMEN1KMT2AALDH1A1
SCHEMBL1129430 0.82 MAPT (0.55) NAMPTGPR119RETMAPTDDB1
SCHEMBL3481867 0.81 ESR2 (0.37) MAPTMEN1KMT2AALDH1A1MAPK1
SCHEMBL15586642 0.79 NAMPT (0.52) NAMPTGPR119RETMAPTKDM4E
SCHEMBL12117456 0.79 GPR119 (0.65) NAMPTGPR119MAPTKDM4ETHRB
SCHEMBL3854559 0.79 NAMPT (0.61) NAMPTGPR119MAPTKDM4ETHRB
SCHEMBL15330866 0.78 PDE4B (0.56) NAMPTGPR119MAPTKDM4ETHRB
SCHEMBL12321681 0.77 NAMPT (0.60) NAMPTGPR119MAPTKDM4ETHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2015-12-24 US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 US disclosed
EP-2282742-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE Infinity Pharmaceuticals, Inc. (US) 2011-02-16 EP disclosed
WO-2009126691-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC (US) 2009-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 NAMPT 740/4885GPR119 213/4885RET 4038/4885
US-20150368278-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 NAMPT 740/4885GPR119 213/4885RET 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.